Annual report pursuant to Section 13 and 15(d)

10. Stockholders' Equity (Tables)

10. Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

	Series B						Series C						Series D						Series E						Series G						Series H						Total
	Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares				Amount
December 31, 2014		5,000		$	1			–		$	–			200,000		$	20			100,000			10			–		$	–			–		$	–			305,000			$31
Conversion of preferred stock into common stock														(200,000	)		(20	)		(55,000	)		(6	)														(255,000	)		(26)
Balance at November 2, 2015		5,000			1			–			–			–			–			45,000			4			–			–			–			–			50,000			5
Cancellation of Medytox shares		(5,000	)		(1	)		–			–			–			–			(45,000	)		(4	)														(50,000	)		(5)
Issuance of Rennova shares		5,000			50															45,000			450															50,000			500
Stock issued for cash, net of offering costs		–			–			9,000			90			–			–			–			–															9,000			90
Balance at December 31, 2015		5,000			50			9,000			90			–			–			45,000			450			–			–			–			–			59,000			590
Conversion of Series C Preferred shares into common stock								(260	)		(3	)																										(260	)		(3)
Exchange of Series C Preferred Stock and warrants for Series G Preferred Stock and warrants								(8,740	)		(87	)														13,793			138									5,053			51
Conversion of Series G Preferred Stock into common stock																										(5,232	)		(53	)								(5,232	)		(53)
Conversion of Series B Preferred shares into common stock		(5,000	)		(50	)																																(5,000	)		(50)
Cancellation of Series E Preferred Stock																				(45,000	)		(450	)														(45,000	)		(450)
Issuance of Series H Preferred Stock for cash																																12,350			124			12,350			124
Redemption of Series G Preferred Stock																										(8,346	)		(83	)								(8,346	)		(83)
Conversion of Series H Preferred Stock into common stock																																(2,331	)		(24	)		(2,331	)		(24)
Balance at December 31, 2016		–		$	–			–		$	–			–		$	–			–		$	–			215		$	2			10,019		$	100			10,234		$	102

Summary of option activity

	Number of options			Weighted-average exercise price		Weighted-average contractual term
Outstanding at December 31, 2014		263,367		$	205.97		4.48
Granted		5,059		$	292.80
Expired		(203,373	)	$	221.13
CollabRx merger		1,957		$	1,270.60
Exercised		(13,654	)	$	75.00
Outstanding at December 31, 2015		53,356		$	231.96		2.90
Granted		693,287		$	118.55
Expired		(4,284	)	$	28.69
Forfeit		(33,334	)	$	21.60
Outstanding at December 31, 2016		709,025		$	129.43
Exercisable at December 31, 2016		635,690		$	145.84		8.93

Shares approved for issuance at plan inception	2,048,189
Options granted in 2014	(587,830	)
Options cancelled in 2014	4,096
Restricted shares issued in 2014	(86,024	)
Balance at December 31, 2014	1,378,431
Options granted in 2015	(364,578	)
Options cancelled in 2015	92,168
Plan cancellation	(1,106,021	)
Balance at December 31, 2015	–

Schedule of stock option activity by exercise price

Options outstanding										Options vested and exercisable
Exercise price		Number outstanding		Weighted average remaining contractual life (years)		Weighted average exercise		Aggregate intrinsic value		Number vested		Weighted average exercise		Aggregate intrinsic value
	$1,270.60		1,957		6.13		$1,270.60	$	–		1,957		$1,270.60
	$300.00		166,667		9.50		$300.00				166,667		$300.00
	$292.24		4,363		8.54		$292.24				4,363		$292.24
	$183.09		47,037		1.28		$183.09				47,037		$183.09
	$150.00		166,667		9.50		$150.00				166,667		$150.00
	$30.00		164,084		9.50		$30.00				147,415		$30.00
	$9.00		158,250		9.54		$9.00		–		101,584		$9.00		–
			709,025				$129.43	$	–		635,690		$145.84	$	–

Warrant activity

	Number of warrants			Weighted average exercise price
Balance at December 31, 2014		–		$	–
Warrants issued during the year		215,054		$	58.13
Warrants assumed in the Merger		14,899		$	6.90
Balance at December 31, 2015		229,953		$	1.83
Cashless exercises		(3,079	)	$	6.90
Exchange of December 30, 2015 warrants		(215,054	)	$	58.13
Exchange Warrants issued		341,651		$	13.50
Warrants issued during the period		1,054,176		$	11.21
Balance at December 31, 2016		1,407,647		$	11.70

Summary of option activity in the Plan

Shares approved for issuance at plan inception	2,048,189
Options granted in 2014	(587,830	)
Options cancelled in 2014	4,096
Restricted shares issued in 2014	(86,024	)
Balance at December 31, 2014	1,378,431
Options granted in 2015	(364,578	)
Options cancelled in 2015	92,168
Plan cancellation	(1,106,021	)
Balance at December 31, 2015	–

- Definition

Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.

+ References + Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details